Orlando Harmon
There is a growing body of research that explores the use of financial incentives to promote healthy behaviors and medication adherence among patients. The idea is that insurers could encourage patients to take preventative measures and make healthier choices, reducing the need for costly treatments in the long run. For example, Volpp and colleagues found that a $750 incentive led to a three-fold increase in the number of people able to quit smoking. Similarly, a patient incentive program in South Africa, which offered rewards like discounted travel or cell phone airtime, increased the use of preventive care services. These programs are based on the concept of shared value, where insurers can monetize better individual behavior, leading to lower-priced premiums. While these incentive programs have shown promising results, there are also ethical considerations and potential unintended consequences, especially for vulnerable populations, that need to be carefully addressed.
| Characteristics | Values |
|---|---|
| Type of Incentive | Financial |
| Target Population | People Living with HIV |
| Intervention | Client-centered incentives approach |
| Mechanism | Redistributive justice |
| Goal | Address social barriers to adherence and resulting health inequities |
| Outcome | Improved antiretroviral (ARV) adherence |
| Cost | Paying for adherence is cost-effective |
| Benefits | Improved individual and public health outcomes, reduced avoidable healthcare costs |
| Ethical Considerations | Commodification of treatment, maleficence |
| Study Design | Qualitative interviews, field notes |
| Sample Size | 30 |
| Framework | Stages-of-change (SOC) model |
| Results | Improved ARV adherence, established client agency, promoted resource redistribution |
Explore related products
What You'll Learn
Financial incentives for patients with HIV
Financial incentives have been shown to improve antiretroviral (ARV) adherence for people living with HIV. However, some scholars have debated the ethics of commodifying treatment in this way.
One study found that financial incentives did not increase linkage to care, but they did significantly increase viral suppression. The overall proportion of patients with viral suppression was 3.8% higher at financial incentive sites compared to standard care sites. Another study found that financial incentives can increase the uptake of HIV testing.
In New York and Washington, DC, a large randomized trial evaluated the effect of coupons redeemable for gift cards at the time of linkage to care and for clinic visits. The trial also assessed the impact of a gift card on a quarterly basis for undetectable viral load. However, there was no significant increase in reaching study outcomes in the incentive arm.
In another example, participants at financial incentive test sites who tested positive for HIV received coupons redeemable for $125 cash-equivalent gift cards upon linkage to care. HIV-positive patients receiving antiretroviral therapy at financial incentive care sites received $70 gift cards quarterly if virally suppressed.
One argument in favor of financial incentives is that they support an ethical service provision framework by establishing and strengthening client agency, revising organizational protocols to prioritize adherence, and promoting resource redistribution.
Group Life Insurance: Myths and Facts About Coverage
You may want to see also
Explore related products
Incentives for physicians to encourage patient medication adherence
Pay-for-performance schemes that incentivize physicians to improve healthcare quality have become increasingly common. However, there is a shortage of robust evidence on their effectiveness in improving patient outcomes. Studies that find positive effects tend to be those where the examined outcome is under physicians' direct control, such as screening and preventive services. In contrast, studies on intermediate health outcomes like blood pressure and blood glucose levels show inconsistent results.
A study conducted from January 2011 to December 2012 tested the effectiveness of physician incentives in increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. The study involved 911 primary care practices and 8,935 non-adherent patients and measured medication adherence for 18 months before and after the intervention. The results showed no evidence that physician incentives increased adherence in any drug class.
Another study that provided financial incentives of $50 per patient per drug class also found that these incentives were not effective in increasing patient medication adherence. However, it was suggested that significant changes in the incentive amount or program design may be necessary to elicit a response from physicians or patients.
To improve patient medication adherence, it is essential to focus on fostering a strong patient-provider relationship and improving communication. Providers can increase awareness, serve as role models, and share personal testimonies to encourage compliance. Additionally, adopting consented reminders via text messages, emails, automated calls, or mailed letters can help mitigate forgetfulness and improve adherence.
Furthermore, embracing partnerships between providers' organizations and community organizations can drive adherence. Adapting the physical properties, bioavailability, and dosage regimens of medications to accommodate diverse patient preferences can also encourage refills and compliance. While financial incentives have been shown to improve medication adherence in some vulnerable populations, there are ethical considerations and debates around the commodification of treatment.
Life Insurance Simplified: Understanding T80 Policies
You may want to see also
Explore related products
Patient incentive programs for preventive care
A study of a patient incentive program in South Africa, including almost 1.5 million enrollees, found that the program increased the use of preventive care. The program works by rewarding enrollees with points for receiving preventive care services, which can be redeemed for discounts on travel or airtime for cell phones. The study showed an estimated increase in the receipt of prevention of 3 to 9 percentage points, or a relative 19 to 97 percent increase.
Another example of a successful patient incentive program is the one targeting people living with HIV. This program used financial incentives to improve antiretroviral (ARV) adherence among socially vulnerable populations. The program was found to be effective in increasing ARV adherence, reducing viral loads, and improving individual and public health outcomes. It also addressed social barriers to adherence, such as housing, and promoted resource redistribution.
These programs are based on the understanding that people often overconsume healthcare but underconsume prevention, leading to higher costs for insurers and taxpayers. By incentivizing preventive behaviours, insurers can improve the health of their customers while also reducing their own costs.
However, it is important to consider the ethical implications of using financial incentives to motivate patients. Some scholars argue that this commodifies treatment and may not be appropriate for all populations. Additionally, the incentive structure used in these programs may not be sustainable in the long term.
Amica's Life Insurance: What You Need to Know
You may want to see also
Explore related products
Ethical considerations of commodifying treatment
The commodification of healthcare refers to the treatment of healthcare as a commodity within a competitive marketplace, where the price, cost, quality, availability, and distribution of healthcare services are dictated by market forces. This shift from a professional ethic to a market-driven approach has raised ethical concerns, particularly regarding the impact on the patient-healthcare professional relationship and the potential prioritization of profits over patients.
One key ethical consideration is the potential conflict between the financial incentives of insurers and the best interests of patients. In a commodified healthcare system, insurers may prioritize profits over providing necessary care, resulting in situations where patients face barriers to accessing certain treatments or encounter opaque and inequitable pricing. This can lead to delayed diagnoses and poorer health outcomes, particularly for vulnerable or underserved populations.
The use of financial incentives to encourage patient adherence to treatment plans further complicates the ethical landscape. While financial incentives have been shown to improve medication adherence, particularly for vulnerable populations, it also raises questions about the commodification of treatment. Scholars debate the ethics of incentivizing treatment adherence, with concerns arising around the potential for unintended harm and the impact on patient autonomy and agency.
Additionally, the commodification of healthcare can lead to the marginalization of certain patient groups. For example, for-profit insurance companies may be selective about their clientele, accepting only younger and healthier patients who are less likely to require expensive treatments. This practice can result in discrimination against older or higher-risk individuals, further exacerbating existing health inequities.
Furthermore, the commodification of healthcare intersects with broader societal issues, such as the role of market forces in determining the value and exchange of goods and services. Healthy volunteers in clinical trials, for instance, may question whether they are “selling or renting” their bodies and the ethical implications of such transactions.
In conclusion, the ethical considerations of commodifying treatment in healthcare are complex and far-reaching. While financial incentives can play a role in improving patient adherence and outcomes, the potential negative consequences, including the impact on the patient-healthcare professional relationship, the prioritization of profits, and the marginalization of vulnerable populations, cannot be overlooked.
Life Insurance: Finalizing Your Family's Future Protection
You may want to see also
Explore related products
The impact of incentives on vulnerable populations
The use of financial incentives to encourage adherence to medication among vulnerable populations has been studied, with some positive outcomes. For instance, in the case of HIV patients, financial incentives have been shown to improve antiretroviral (ARV) adherence. This approach, rooted in principles of client self-reliance and economic justice, also helped address social barriers to adherence and resulting health inequities.
However, the ethical implications of such incentives have been debated. Some scholars argue that financial incentives commodify treatment, and there are concerns about the potential for coercion or undue influence, especially with vulnerable populations. For example, in surveys of violence and injury, monetary incentives are often used to facilitate recruitment and motivate participation, but this could potentially exert undue influence on respondents.
To address these concerns, it is recommended that participants are adequately informed about the nature and purpose of the intervention or survey, and that their agency is established and strengthened. Additionally, organizational protocols should be revised to prioritize adherence, and resources should be redistributed to address social barriers.
Overall, while financial incentives can be effective in encouraging medication adherence among vulnerable populations, it is important to carefully consider the ethical implications and take steps to ensure the protection of participants.
Ethos Life Insurance: Cheap, But Why?
You may want to see also
Frequently asked questions
Incentivizing patients can help to improve individual and public health outcomes and reduce avoidable healthcare costs.
Yes, scholars have argued that incentivizing patients commodifies treatment.
Incentives can include monetary rewards, discounted travel, or airtime for a cellphone.
Patient incentive programs have been shown to be effective in promoting healthy behaviors. For example, a $750 incentive led to a three-fold increase in the number of people able to quit smoking.
Patient incentive programs typically work by offering rewards or discounts to patients who participate in preventive care services or healthy behaviors. These rewards can be earned through accumulating points or meeting certain goals.
